Shanghai Raas Blood Products Co., Ltd.
Clinical trials sponsored by Shanghai Raas Blood Products Co., Ltd., explained in plain language.
A Chinese blood products company manufacturing plasma-derived therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New shot aims to tame bleeding disorder in small trial
Disease control Recruiting nowThis Phase 2 trial tests an injection called SR604 in 24 adults with von Willebrand disease, a bleeding disorder. The goal is to see if it safely reduces the number of bleeding episodes. Participants receive multiple doses, and researchers track bleeding rates and quality of life…
Phase: PHASE2 • Sponsor: Shanghai RAAS Blood Products Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New shot aims to cut bleeding in hemophilia patients
Disease control Recruiting nowThis study tests an experimental injection called SR604 in 76 adults with hemophilia A, B, or congenital factor VII deficiency. The goal is to see if it is safe and can reduce bleeding episodes. Participants will receive either a single dose or multiple doses, and researchers wil…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai RAAS Blood Products Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC